Arbutus Biopharma(GB:0SGC)
$3.320.00 (0.00%)
GB:0SGC
Arbutus Biopharma ownership
$3.32
At close:0.00 (0.00%)
Arbutus Biopharma (0SGC) Ownership - Who Owns Arbutus Biopharma?
1 Followers
Arbutus Biopharma (0SGC) Ownership Overview
- 19.68% Insiders
- 12.34% Mutual Funds
- 28.01% Other Institutional Investors
- 14.39% ETFs
- 25.57% Public Companies and Individual Investors
The ownership structure of Arbutus Biopharma (GB:0SGC) stock is a mix of institutional, retail, and individual investors. Approximately 54.75% of the company’s stock is owned by Institutional Investors, 19.68% is owned by Insiders, and 25.57% is owned by Public Companies and Individual Investors.
Institutional holdings as of
The ownership structure of Arbutus Biopharma (GB:0SGC) stock is a mix of institutional, retail, and individual investors. Approximately 54.75% of the company’s stock is owned by Institutional Investors, 19.68% is owned by Insiders, and 25.57% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Entrypoint Capital, Llc | $363,669 | |
| Dec 31, 2025 | Saba Capital Management | $1,673,326 | |
| Dec 31, 2025 | Woodline Partners Lp | $10,517,319 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 29,880,079 | Insider | 19.49% | 99,142,102 |
| BlackRock, Inc. | 14,515,428 | Institution | 9.47% | 48,162,190 |
| Ishares | 8,329,711 | Institution | 5.43% | 27,637,981 |
| Vanguard Index Funds | 6,829,678 | Institution | 4.46% | 22,660,872 |
| Vanguard | 6,023,848 | Institution | 3.93% | 19,987,128 |
| Spdr | 4,112,904 | Institution | 2.68% | 13,646,615 |
| Morgan Stanley Insight Fund | 2,728,775 | Institution | 1.78% | 9,054,075 |
| Michael Rockefeller | 2,281,856 | Institution | 1.49% | 7,571,198 |
| Morgan Stanley Institutional Fund Inc | 1,978,273 | Institution | 1.29% | 6,563,910 |
| Fidelity Salem Street Trust | 1,933,959 | Institution | 1.26% | 6,416,876 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 6,829,678 | Institution | 4.46% | 22,660,872 |
| Morgan Stanley Insight Fund | 2,728,775 | Institution | 1.78% | 9,054,075 |
| Morgan Stanley Institutional Fund Inc | 1,978,273 | Institution | 1.29% | 6,563,910 |
| Fidelity Salem Street Trust | 1,933,959 | Institution | 1.26% | 6,416,876 |
| Fidelity Concord Street Trust | 1,585,423 | Institution | 1.03% | 5,260,434 |
| Vanguard Scottsdale Funds | 1,110,321 | Institution | 0.72% | 3,684,045 |
| Tiaa-cref Funds | 511,796 | Institution | 0.33% | 1,698,139 |
| Schwab Capital Trust | 489,116 | Institution | 0.32% | 1,622,887 |
| Vanguard World Fund | 435,449 | Institution | 0.28% | 1,444,820 |
| Goldman Sachs Trust | 385,130 | Institution | 0.25% | 1,277,861 |
FAQ
Who Owns Arbutus Biopharma (GB:0SGC)?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 54.75% of the company's stock is held by institutional investors, 19.68% is held by insiders, and 25.57% is held by public companies and individual investors.
What percentage of Arbutus Biopharma (GB:0SGC) stock is held by institutional investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 54.75% of Arbutus Biopharma (GB:0SGC) stock is held by institutional investors: 12.34% by mutual funds, 14.39% by ETFs and 28.01% by other institutional investors.
What percentage of Arbutus Biopharma (GB:0SGC) stock is held by retail investors?
According to the latest TipRanks data (13F holdings as of December 31, 2025), approximately 25.57% of Arbutus Biopharma (GB:0SGC) stock is held by public companies and individual investors.
Who owns the most shares of Arbutus Biopharma (GB:0SGC)?
Roivant Sciences Ltd. owns the most shares of Arbutus Biopharma (GB:0SGC).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.

